SibleyWABamfordCRClarkK. Clinical viral infections and multiple sclerosis. Lancet1985; 1: 1313–5.
5.
TeitelbaumDMeshoreiAHirshfieldTArnonR. M. S. Suppression of experimental allergic encephalomyelitis by a synthetic peptide. Eur J Immunol1971; 1: 242–8.
6.
AbramskyOTeitelbaumDArnonR. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. Journal of the Neurological Sciences1977; 31: 433–8.
7.
BornsteinMBMillerASlagleS. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med1987; 317: 408–14.
8.
WaynerEACarterWGPiotrowiczRSKunickiTJ. The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa. Journal of Cell Biology1988; 107: 1881–91.
9.
YednockTACannonCFritzLCSanchez-MadridFSteinmanL. N. K. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–6.
10.
MiSHuBHahmK. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med2007; 13: 1228–33.
11.
HaleGBrightSChumbleyG. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood1983; 62: 873–82.
12.
TradtrantipLZhangHSaadounS. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol2012; 71: 314–22.